vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and ROGERS CORP (ROG). Click either name above to swap in a different company.
LivaNova PLC is the larger business by last-quarter revenue ($360.9M vs $200.5M, roughly 1.8× ROGERS CORP). LivaNova PLC runs the higher net margin — 8.6% vs 2.2%, a 6.3% gap on every dollar of revenue. On growth, LivaNova PLC posted the faster year-over-year revenue change (12.1% vs 5.2%). LivaNova PLC produced more free cash flow last quarter ($50.2M vs $1.1M). Over the past eight quarters, LivaNova PLC's revenue compounded faster (10.6% CAGR vs -3.3%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
LIVN vs ROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $200.5M |
| Net Profit | $30.9M | $4.5M |
| Gross Margin | 65.2% | 32.2% |
| Operating Margin | 11.8% | — |
| Net Margin | 8.6% | 2.2% |
| Revenue YoY | 12.1% | 5.2% |
| Net Profit YoY | -44.7% | 421.4% |
| EPS (diluted) | $0.57 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $200.5M | ||
| Q4 25 | $360.9M | $201.5M | ||
| Q3 25 | $357.8M | $216.0M | ||
| Q2 25 | $352.5M | $202.8M | ||
| Q1 25 | $316.9M | $190.5M | ||
| Q4 24 | $321.8M | $192.2M | ||
| Q3 24 | $318.1M | $210.3M | ||
| Q2 24 | $318.6M | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | $30.9M | $4.6M | ||
| Q3 25 | $26.8M | $8.6M | ||
| Q2 25 | $27.2M | $-73.6M | ||
| Q1 25 | $-327.3M | $-1.4M | ||
| Q4 24 | $55.9M | $-500.0K | ||
| Q3 24 | $33.0M | $10.7M | ||
| Q2 24 | $16.3M | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | 65.2% | 31.5% | ||
| Q3 25 | 68.4% | 33.5% | ||
| Q2 25 | 67.8% | 31.6% | ||
| Q1 25 | 69.7% | 29.9% | ||
| Q4 24 | 68.2% | 32.1% | ||
| Q3 24 | 70.8% | 35.2% | ||
| Q2 24 | 68.7% | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 3.5% | ||
| Q3 25 | 15.1% | 7.3% | ||
| Q2 25 | 15.4% | -33.3% | ||
| Q1 25 | 15.3% | -0.2% | ||
| Q4 24 | 11.5% | -6.6% | ||
| Q3 24 | 11.2% | 6.9% | ||
| Q2 24 | 12.6% | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | 8.6% | 2.3% | ||
| Q3 25 | 7.5% | 4.0% | ||
| Q2 25 | 7.7% | -36.3% | ||
| Q1 25 | -103.3% | -0.7% | ||
| Q4 24 | 17.4% | -0.3% | ||
| Q3 24 | 10.4% | 5.1% | ||
| Q2 24 | 5.1% | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.57 | $0.20 | ||
| Q3 25 | $0.49 | $0.48 | ||
| Q2 25 | $0.50 | $-4.00 | ||
| Q1 25 | $-6.01 | $-0.08 | ||
| Q4 24 | $1.04 | $-0.04 | ||
| Q3 24 | $0.60 | $0.58 | ||
| Q2 24 | $0.30 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | $195.8M |
| Total DebtLower is stronger | $376.1M | — |
| Stockholders' EquityBook value | $1.2B | $1.2B |
| Total Assets | $2.6B | $1.4B |
| Debt / EquityLower = less leverage | 0.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $195.8M | ||
| Q4 25 | $635.6M | $197.0M | ||
| Q3 25 | $646.1M | $167.8M | ||
| Q2 25 | $593.6M | $157.2M | ||
| Q1 25 | $738.4M | $175.6M | ||
| Q4 24 | $428.9M | $159.8M | ||
| Q3 24 | $346.4M | $146.4M | ||
| Q2 24 | $329.2M | $119.9M |
| Q1 26 | — | — | ||
| Q4 25 | $376.1M | — | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | $1.2B | $1.2B | ||
| Q2 25 | $1.1B | $1.2B | ||
| Q1 25 | $1.0B | $1.3B | ||
| Q4 24 | $1.3B | $1.3B | ||
| Q3 24 | $1.3B | $1.3B | ||
| Q2 24 | $1.2B | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.6B | $1.4B | ||
| Q3 25 | $2.6B | $1.4B | ||
| Q2 25 | $2.5B | $1.5B | ||
| Q1 25 | $2.6B | $1.5B | ||
| Q4 24 | $2.5B | $1.5B | ||
| Q3 24 | $2.5B | $1.5B | ||
| Q2 24 | $2.5B | $1.5B |
| Q1 26 | — | — | ||
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | $5.8M |
| Free Cash FlowOCF − Capex | $50.2M | $1.1M |
| FCF MarginFCF / Revenue | 13.9% | 0.5% |
| Capex IntensityCapex / Revenue | 8.9% | 2.3% |
| Cash ConversionOCF / Net Profit | 2.67× | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $82.4M | $46.9M | ||
| Q3 25 | $85.1M | $28.9M | ||
| Q2 25 | $62.9M | $13.7M | ||
| Q1 25 | $24.0M | $11.7M | ||
| Q4 24 | $78.7M | $33.7M | ||
| Q3 24 | $51.0M | $42.4M | ||
| Q2 24 | $43.4M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $50.2M | $42.2M | ||
| Q3 25 | $62.2M | $21.2M | ||
| Q2 25 | $47.8M | $5.6M | ||
| Q1 25 | $13.2M | $2.1M | ||
| Q4 24 | $68.3M | $18.3M | ||
| Q3 24 | $32.8M | $25.2M | ||
| Q2 24 | $31.2M | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 13.9% | 20.9% | ||
| Q3 25 | 17.4% | 9.8% | ||
| Q2 25 | 13.6% | 2.8% | ||
| Q1 25 | 4.2% | 1.1% | ||
| Q4 24 | 21.2% | 9.5% | ||
| Q3 24 | 10.3% | 12.0% | ||
| Q2 24 | 9.8% | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 8.9% | 2.3% | ||
| Q3 25 | 6.4% | 3.6% | ||
| Q2 25 | 4.3% | 4.0% | ||
| Q1 25 | 3.4% | 5.0% | ||
| Q4 24 | 3.2% | 8.0% | ||
| Q3 24 | 5.7% | 8.2% | ||
| Q2 24 | 3.8% | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | 2.67× | 10.20× | ||
| Q3 25 | 3.18× | 3.36× | ||
| Q2 25 | 2.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.41× | — | ||
| Q3 24 | 1.55× | 3.96× | ||
| Q2 24 | 2.65× | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
ROG
Segment breakdown not available.
